Rathbones Group’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.14M Sell
14,271
-2,424
-15% -$200K ﹤0.01% 348
2025
Q4
$1.42M Sell
16,695
-71,276
-81% -$5.85M 0.01% 331
2025
Q3
$6.84M Sell
87,971
-40,645
-32% -$3.18M 0.03% 183
2025
Q2
$10.1M Sell
128,616
-499,459
-80% -$37.2M 0.04% 162
2025
Q1
$45.5M Sell
628,075
-671,096
-52% -$48M 0.22% 98
2024
Q4
$96.2M Buy
1,299,171
+15,192
+1% +$1.06M 0.47% 55
2024
Q3
$84.7M Buy
1,283,979
+363,051
+39% +$26.4M 0.43% 64
2024
Q2
$85.1M Buy
920,928
+32,422
+4% +$2.87M 0.46% 58
2024
Q1
$84.9M Buy
888,506
+75,529
+9% +$6.34M 0.49% 52
2023
Q4
$62M Buy
812,977
+90,025
+12% +$6.26M 0.4% 61
2023
Q3
$50.1M Buy
722,952
+145,089
+25% +$11.7M 0.36% 65
2023
Q2
$54.5M Buy
577,863
+36,865
+7% +$3.2M 0.51% 54
2023
Q1
$44.8M Buy
540,998
+48,481
+10% +$3.81M 0.46% 59
2022
Q4
$36.7M Buy
492,517
+52,724
+12% +$4.06M 0.41% 64
2022
Q3
$36.3M Buy
439,793
+8,919
+2% +$858K 0.45% 58
2022
Q2
$41M Buy
430,874
+28,635
+7% +$2.96M 0.47% 58
2022
Q1
$47.4M Buy
402,239
+10,101
+3% +$1.13M 0.48% 52
2021
Q4
$50.8M Buy
392,138
+26,049
+7% +$3.04M 0.49% 55
2021
Q3
$41.4M Buy
366,089
+49
+0% +$5.59K 0.45% 58
2021
Q2
$37.9M Buy
366,040
+49,435
+16% +$4.66M 0.42% 60
2021
Q1
$26.5M Buy
316,605
+82,311
+35% +$6.96M 0.34% 75
2020
Q4
$21.4M Buy
234,294
+121,929
+109% +$10.1M 0.3% 78
2020
Q3
$8.97M Buy
112,365
+86,020
+327% +$6.71M 0.15% 95
2020
Q2
$1.82M Buy
26,345
+21,824
+483% +$1.55M 0.04% 170
2020
Q1
$284K Buy
+4,521
New +$326K 0.01% 253

Other funds holding EW

Rathbones Group's EW Position: Q1 2026 in Review

Rathbones Group reduced its Edwards Lifesciences (EW) stake by 15% in Q1 2026, selling an estimated $200K and leaving 14,271 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #348.

Rathbones Group first reported a position in EW in Q1 2020 and has held it in 25 quarters since. The position peaked at $96.2M in Q4 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Rathbones Group held 14,271 shares of Edwards Lifesciences worth $1.14M as of Q1 2026.
  • Rathbones Group sold 2,424 Edwards Lifesciences shares in Q1 2026, an estimated $200K.
  • Edwards Lifesciences made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #348 holding.
  • Rathbones Group first reported a position in Edwards Lifesciences in Q1 2020 and has held it in 25 quarters since.
  • Rathbones Group's Edwards Lifesciences position peaked at $96.2M in Q4 2024.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.